{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:41:49Z","timestamp":1792629709425,"version":"4.5.0"},"reference-count":78,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education, Science and Innovations, Montenegro"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Inflammatory cytokines have been implicated as crucial contributors to the onset and progression of non-alcoholic fatty liver disease (NAFLD). The exact mechanisms by which interleukins (ILs) contribute to NAFLD may vary, and ongoing research is aimed at understanding the specific roles of different ILs in the pathogenesis of this condition. In addition, variations in environmental factors and genetics in each individual can influence the onset and\/or progression of NAFLD. The lack of clinical studies related to the potential therapeutic properties of IL-1 inhibitors currently does not allow us to conclude their validity as a therapeutic option, although preclinical studies show promising results. Further studies are needed to elucidate their beneficial properties in NAFLD treatment.<\/jats:p>","DOI":"10.3390\/metabo14030153","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T05:48:01Z","timestamp":1709704081000},"page":"153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"14","author":[{"given":"Saira","family":"Rafaqat","sequence":"first","affiliation":[{"name":"Department of Zoology, Lahore College for Women University, Lahore 54600, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Gluscevic","sequence":"additional","affiliation":[{"name":"Clinical Center of Montenegro, Department for Neurology, 81000 Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-1534","authenticated-orcid":false,"given":"Filiz","family":"Mercantepe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Recep Tayyip Erdogan University, 53010 Rize, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Rafaqat","sequence":"additional","affiliation":[{"name":"Department of Biotechnology (Human Genetics), Lahore College for Women University, Lahore 54600, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-0996","authenticated-orcid":false,"given":"Aleksandra","family":"Klisic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montenegro, 81000 Podgorica, Montenegro"},{"name":"Center for Laboratory Diagnostics, Primary Health Care Center, 81000 Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"Bugianesi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18455","DOI":"10.1038\/s41598-021-97686-6","article-title":"Oxidative stress and cardiometabolic biomarkers in patients with non-alcoholic fatty liver disease","volume":"11","author":"Klisic","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5114\/aoms.2017.68972","article-title":"Bioavailable testosterone is independently associated with fatty liver index in postmenopausal women","volume":"5","author":"Klisic","year":"2017","journal-title":"Arch. Med Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-0043-118667","article-title":"Relationship between Oxidative Stress, Inflammation and Dyslipidemia with Fatty Liver Index in Patients with Type 2 Diabetes Mellitus","volume":"126","author":"Klisic","year":"2018","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","article-title":"Immunological mechanisms and therapeutic targets of fatty liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_7","unstructured":"Vaillant, A.A.J., and Qurie, A. (2023). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mertowska, P., Mertowski, S., Smarz-Widelska, I., and Grywalska, E. (2022). Biological Role, Mechanism of Action and the Importance of Interleukins in Kidney Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020647"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"872155","DOI":"10.3389\/fimmu.2022.872155","article-title":"What is IL-1 for? The functions of interleukin-1 across evolution","volume":"13","author":"Boraschi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000444547","article-title":"Non-alcoholic steatohepatitis: From pathophysiology to novel therapies","volume":"34","author":"Jahn","year":"2016","journal-title":"Dig. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dimosiari, A., Patoulias, D., Kitas, G.D., and Dimitroulas, T. (2023). Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041302"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107765","DOI":"10.1016\/j.intimp.2021.107765","article-title":"Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies","volume":"96","author":"Ghanbari","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2018.03.005","article-title":"IL-1 family cytokine pathways underlying NAFLD: Towards new treatment strategies","volume":"24","author":"Mirea","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1048","DOI":"10.1002\/ctm2.1048","article-title":"Hepatic interleukin-1 receptor type 1 signalling regulates insulin sensitivity in the early phases of nonalcoholic fatty liver disease","volume":"12","author":"Gehrke","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hohenester, S., Kanitz, V., Schiergens, T., Einer, C., Nagel, J., Wimmer, R., Reiter, F.P., Gerbes, A.L., De Toni, E.N., and Bauer, C. (2020). IL-18 but not IL-1 signaling is pivotal for the initiation of liver injury in murine non-alcoholic fatty liver disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228602"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41598-022-26896-3","article-title":"IL-1\u03b2 neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH","volume":"13","author":"Kucsera","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.livres.2018.03.003","article-title":"Cytokines and fatty liver diseases","volume":"2","author":"Niederreiter","year":"2018","journal-title":"Liver Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101710","DOI":"10.1016\/j.clinre.2021.101710","article-title":"Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target","volume":"45","author":"Colak","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2011.10.005","article-title":"Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans","volume":"56","author":"Kuulasmaa","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21303\/2504-5679.2021.001854","article-title":"IL-1\u03b2 and IL-10: Diagnostic and prognostic potential of cytokines in the assessment of progression of non-alcoholic fatty liver disease in patients with hypertension","volume":"5","author":"Zhelezniakova","year":"2021","journal-title":"EUREKA Health Sci."},{"key":"ref_22","first-page":"327","article-title":"Circulating levels of pro-inflammatory cytokines in patients with nonalcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"16","author":"Hadinia","year":"2019","journal-title":"Iran. J. Immunol."},{"key":"ref_23","first-page":"381","article-title":"The serum levels of IL-1\u03b2, IL-6, IL-8 and TNF-\u03b1 in nonalcoholic fatty liver","volume":"33","author":"Hanefi","year":"2003","journal-title":"Turk. J. Med. Sci."},{"key":"ref_24","first-page":"52","article-title":"Development of Non-alcoholic Fatty Liver Disease (NAFLD) in Young Obese Tribal Subjects of Tripura: Link between Low 25 (OH) Vitamin-D Levels and Immune Modulators","volume":"67","author":"Chakraborty","year":"2019","journal-title":"J. Assoc. Physicians India"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24321\/2349.7181.201906","article-title":"Evaluation of Pro-Inflammatory Markers IL-6 and TNF-a and their Correlation with Non-Alcoholic Fatty Liver Disease","volume":"6","author":"Khura","year":"2019","journal-title":"J. Adv. Res. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, F., Mi, J., Bai, X., Ruan, G., Zhang, Y., and Yu, K. (2022). Interleukins and the risk of non-alcoholic fatty liver disease: A two-sample Mendelian randomization study. Res. Sq., posted.","DOI":"10.21203\/rs.3.rs-1751879\/v2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.livres.2018.02.003","article-title":"Role of sterile inflammation in fatty liver diseases","volume":"2","author":"Chen","year":"2018","journal-title":"Liver Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0065-2776(08)60844-5","article-title":"The interleukin 2 receptor","volume":"42","author":"Smith","year":"1988","journal-title":"Adv. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/JCMA.0000000000000469","article-title":"Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis","volume":"84","author":"Kao","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.28776","article-title":"Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease","volume":"65","author":"Ajmera","year":"2017","journal-title":"Hepatology"},{"key":"ref_31","first-page":"78","article-title":"Inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD) in obese children and adolescents","volume":"35","author":"Sorte","year":"2018","journal-title":"Nutr. Hosp."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.v17.i1.10","article-title":"Functions of IL-4 and control of its expression","volume":"17","author":"Brown","year":"1997","journal-title":"Crit. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12291-011-0121-7","article-title":"Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease","volume":"26","author":"Das","year":"2011","journal-title":"Indian J. Clin. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3889\/oamjms.2021.7016","article-title":"Dynamics of Pro-and Anti-inflammatory Cytokines in Experimental Animals with Non-alcoholic Fatty Liver Disease Under Conditions of Hypobaric Hypoxia","volume":"9","author":"Toktogulova","year":"2021","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0952-7915(92)90080-X","article-title":"Interleukin-5","volume":"4","author":"Takatsu","year":"1992","journal-title":"Curr. Opin. Immunol."},{"key":"ref_36","first-page":"21","article-title":"Comparison the Effects of Vitamin E and Propolis on Interleukin-5 and STAT1 Gene Expression in Wistar Rats with Non-alcoholic Fatty Liver Disease","volume":"15","author":"Baarforoush","year":"2023","journal-title":"J. Anim. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/pro.5560060501","article-title":"Interleukin-6: Structure-function relationships","volume":"6","author":"Simpson","year":"1997","journal-title":"Protein Sci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mas, E., Danjoux, M., Garcia, V., Carpentier, S., S\u00e9gui, B., and Levade, T. (2009). IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007929"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1572-0241.2007.01774.x","article-title":"Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis","volume":"103","author":"Wieckowska","year":"2008","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"905936","DOI":"10.3389\/fphar.2022.905936","article-title":"Interleukin-6 receptor blockade can increase the risk of nonalcoholic fatty liver disease: Indications from mendelian randomization","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000282083","article-title":"The role of cytokines in non-alcoholic fatty liver disease","volume":"28","author":"Tilg","year":"2010","journal-title":"Dig. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/labinvest.2010.75","article-title":"Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice","volume":"90","author":"Yamaguchi","year":"2010","journal-title":"Lab. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","article-title":"IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease","volume":"78","author":"Park","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10517-023-05759-5","article-title":"The Role of the Soluble Interleukin-6 Receptor in the Progression of Nonalcoholic Fatty Liver Disease","volume":"174","author":"Krbatuova","year":"2023","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.2337\/db23-0171","article-title":"IL-6 Trans-Signaling Is Increased in Diabetes, Impacted by Glucolipotoxicity, and Associated with Liver Stiffness and Fibrosis in Fatty Liver Disease","volume":"72","author":"Gunes","year":"2023","journal-title":"Diabetes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4172\/2469-9756.1000131","article-title":"Effects of non-alcoholic fatty liver disease on visfatin and IL-6 levels in mice: An immunohistochemical study","volume":"4","author":"Ozgocmen","year":"2018","journal-title":"Immunochem. Immunopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"hcaa052.048","DOI":"10.1093\/qjmed\/hcaa052.048","article-title":"A study of Interleukin 6 as a predictive biomarker for development of nonalcholic steatohepatitis in patients with Nonalcholic fatty liver disease","volume":"113","author":"Mohamed","year":"2020","journal-title":"QJM Int. J. Med."},{"key":"ref_48","first-page":"4161","article-title":"\u201cInterleukin-six\u201d As Predictor of \u201cNon Alcoholic Fatty Liver Disease\u201d among \u201cInsulin Resistance Syndrome\u201d: A study protocol","volume":"25","author":"Patel","year":"2021","journal-title":"Ann. Rom. Soc. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/1753425909104900","article-title":"Interleukin-6 is associated with liver lipid homeostasis but not with cell death in experimental hepatic steatosis","volume":"15","author":"Chico","year":"2009","journal-title":"Innate Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1665-2681(19)31635-7","article-title":"Visceral adipose tissue visfatin in nonalcoholic fatty liver disease","volume":"9","author":"Gaddipati","year":"2010","journal-title":"Ann. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13312-017-1143-x","article-title":"Relationship between immune parameters and non-alcoholic fatty liver disease in obese children","volume":"54","author":"Shi","year":"2017","journal-title":"Indian Pediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1359-6101(98)00025-2","article-title":"Interleukin-7: Physiological roles and mechanisms of action","volume":"10","author":"Hofmeister","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/hep4.1068","article-title":"Association between cytokines and liver histology in children with nonalcoholic fatty liver disease","volume":"1","author":"Perito","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_54","first-page":"456","article-title":"The role of interleukin-8 in inflammation and mechanisms of regulation","volume":"64","author":"Bickel","year":"1993","journal-title":"J. Periodontol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Auguet, T., Bertran, L., Binetti, J., Aguilar, C., Mart\u00ednez, S., Sabench, F., Lopez-Dupla, J.M., Porras, J.A., Riesco, D., and Del Castillo, D. (2020). Relationship between IL-8 circulating levels and TLR2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114189"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e24635","DOI":"10.5812\/hepatmon.24635","article-title":"The role of interleukin-6 and interleukin-8 gene polymorphisms in non-alcoholic steatohepatitis","volume":"14","author":"Cengiz","year":"2014","journal-title":"Hepat. Mon."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.14309\/00000434-201410002-00575","article-title":"IL-8 Is an Important Contributor to Both the Progression of Systematic Inflammation and Increasing Severity of Non-Alcoholic Fatty Liver Disease (NAFLD): 575","volume":"109","author":"Birerdinc","year":"2014","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cho, Y.E., Kim, Y., Kim, S.-J., Lee, H., and Hwang, S. (2023). Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015489"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1590\/s0004-2803.201800000-62","article-title":"Correlation between nonalcoholic fatty liver disease features and levels of adipokines and inflammatory cytokines among morbidly obese individuals","volume":"55","author":"Baltieri","year":"2018","journal-title":"Arq. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep4.1237","article-title":"Serum interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"2","author":"Glass","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_61","unstructured":"Rojas-Zuleta, W.G., and Sanchez, E. (2017). Th9 Cells: Methods and Protocols, Humana Press."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10517-021-05285-2","article-title":"Taurine reduces liver damage in non-alcoholic fatty liver disease model in rats by down-regulating IL-9 and tumor growth factor TGF-\u03b2","volume":"171","author":"Yao","year":"2021","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e20190418","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_64","first-page":"2836","article-title":"Protective mechanism of interleukin-10 against nonalcoholic fatty liver disease and its prospect in treatment","volume":"38","author":"Ruifeng","year":"2022","journal-title":"J. Clin. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4297206","DOI":"10.1155\/2017\/4297206","article-title":"Cytokines genotype-phenotype correlation in nonalcoholic steatohepatitis","volume":"2017","author":"Bocsan","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.35514\/mtd.2021.50","article-title":"Diagnostic capabilities of kallistatin, IL-10 and IL-1\u03b2 in patients with non-alcoholic fatty liver disease and hypertension","volume":"13","author":"Rozhdestvenska","year":"2021","journal-title":"Maltepe T\u0131p Derg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.24517","article-title":"Inflammation-associated interleukin-6\/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10\u2013deficient mice","volume":"54","author":"Miller","year":"2011","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: Pathophysiological concepts and treatment options","volume":"119","author":"Grander","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1150360","DOI":"10.3389\/fendo.2023.1150360","article-title":"Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma","volume":"14","author":"Jeong","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Niederseer, D., Wernly, B., Aigner, E., Stickel, F., and Datz, C. (2021). NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030467"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1046130","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"Niu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13543784.2020.1681397","article-title":"A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?","volume":"29","author":"Tilg","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","first-page":"1186","article-title":"Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update","volume":"10","author":"Kizivat","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/1440-1681.12499","article-title":"Increased ratio of neutrophil elastase to \u03b11-antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis","volume":"43","author":"Zang","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2119\/molmed.2016.00033","article-title":"Activation of proteinase 3 contributes to Non-alcoholic Fatty Liver Disease (NAFLD) and insulin resistance","volume":"22","author":"Toonen","year":"2016","journal-title":"Mol. Med."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/14\/3\/153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:03Z","timestamp":1760105403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/14\/3\/153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["metabo14030153"],"URL":"https:\/\/doi.org\/10.3390\/metabo14030153","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}